FindMyRecallSubscribe
Class III: unlikely to cause harmOngoing

Rubicon Research Private AcetaZOLAMIDE Tablets Recall

AcetaZOLAMIDE Tablets, USP, 125 mg, 100 count bottled, Rx Only, Distributed by: Advagen…

Rubicon Research Private Limited

Risk level
Class III
Reported by FDA
Sep 25, 2024
Recall ID
D-0659-2024
Check your lot numberHow we source this data

Summary

Rubicon Research Private recalled AcetaZOLAMIDE Tablets starting Aug 24, 2024. The FDA classified it as Class III (unlikely to cause harm) and published enforcement report D-0659-2024 on Sep 25, 2024. Reason: Discoloration. Status: Ongoing.

Why it was recalled

Discoloration

Product description

AcetaZOLAMIDE Tablets, USP, 125 mg, 100 count bottled, Rx Only, Distributed by: Advagen Pharma Limited, Plainsboro, NJ, Manufactured by Rubicon Research Private Limited, Thane, India NDC 72888-047-01

Lot numbers, UPCs & expiration codes

Lot # 30575HF1, exp. date, Nov 2026 NDC# 72888-047-01

Where it was sold

Nationwide in the US

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0659-2024
Classification
Class III
Status
Ongoing
Recall initiated
Aug 24, 2024
FDA report date
Sep 25, 2024
Quantity
3,984 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Rubicon Research Private Limited

Original FDA data

Every field from FDA enforcement report D-0659-2024, exactly as published.

Show all FDA fields
City
Ambarnath
Status
Ongoing
Country
India
Event ID
95217
Address
4 & K30 5 Plot No K - 30
Code information
Lot # 30575HF1, exp. date, Nov 2026 NDC# 72888-047-01
Report date
Sep 25, 2024
Product type
Drugs
Recall number
D-0659-2024
Classification
Class III
Recalling firm
Rubicon Research Private Limited
Product quantity
3,984 bottles
Reason for recall
Discoloration
Voluntary / mandated
Voluntary: Firm initiated
Product description
AcetaZOLAMIDE Tablets, USP, 125 mg, 100 count bottled, Rx Only, Distributed by: Advagen Pharma Limited, Plainsboro, NJ, Manufactured by Rubicon Research Private Limited, Thane, India NDC 72888-047-01
Distribution pattern
Nationwide in the US
Recall initiation date
Aug 24, 2024
Initial firm notification
Letter
Center classification date
Sep 13, 2024

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0659-2024, published Sep 25, 2024. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls